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Abstract Hydrophilic matrix systems are currently some of
the most widely used drug delivery systems for controlled-
release oral dosage forms. Amongst a variety of polymers,
polyethylene oxide (PEO) is considered an important material
used in pharmaceutical formulations. As PEO is sensitive to
thermal oxidation, it is susceptible to free radical oxidative
attack. The aim of this study was to investigate the stability
of PEO based formulations containing different model drugs
with different water solubility, namely propranolol HCl, the-
ophylline and zonisamide. Both polyox matrices 750 and 303
grade were used as model carriers for the manufacture of
tablets stored at 40 °C. The results of the present study suggest
that the drug release from the matrix was affected by the
length of storage conditions, solubility of drugs and the mo-
lecular weight of the polymers. Generally, increased drug re-
lease rates were prevalent in soluble drug formulations
(propranolol) when stored at the elevated temperature
(40 °C). In contrast, it was not observed with semi soluble
(theophylline) and poorly soluble (zonisamide) drugs espe-
cially when formulated with PEO 303 polymer. This indicates
that the main parameters controlling the drug release from
fresh polyox matrices are the solubility of the drug in the
dissolution medium and the molecular weight of the polymer.
DSC traces indicated that that there was a big difference in the
enthalpy and melting points of fresh and aged PEO samples
containing propranolol, whereas the melting point of the aged
polyox samples containing theophylline and zonisamide was
unaffected.
Keywords Stability . Polyoxmatrices . Drug release . Drug
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Introduction
Controlled release (CR) deals with dosage forms intended to
provide a therapeutic amount of drug to a specific site or
location at the desired rate [1]. In the recent years, CR systems
have gained much attention and have become an increasingly
important strategy in therapeutic treatment. The underlying
reason is that the CR systems allow the pharmacological effect
to bemaintained by releasing a drug to the desired target site at
a controlled rate for an appropriate extended time. CR formu-
lations have several potential advantages over conventional
dosage forms, such as reducing high total dose, reducing dos-
ing frequency and gastrointestinal (GIT) side effects as well as
improving patient acceptance and compliances [2]. Advances
in research aiming towards fundamental principles to bring
both commercial and therapeutic values to health care prod-
ucts have led to the introduction of a new concept termed as
‘chronotherapy’. It refers to a clinical practice of synchroniz-
ing drug delivery in a manner consistent with the body’s
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circadian rhythm including disease states, to produce maxi-
mum health benefit and minimum harmful effects [3].
Hydrophilic matrix tablets are among the most popular deliv-
ery systems for oral controlled-release dosage forms. These hy-
drophilic matrices are widely accepted because of their biophar-
maceutical and pharmacokinetics advantages over conventional
dosage forms [4]. A hydrophilic matrix tablet generally consists
of a mixture of drug, polymer and excipients such as filler or
diluent as well as other excipients mainly used in common
tableting process [5]. Hydrophilic matrix systems are simple to
formulate, inexpensive and easy to produce and generally have a
good in vitro and in vivo correlation [6]. From the wide choice of
possible matrix materials, polyethylene oxide (PEO) has been
used most frequently in the formulation of CRmonolithic matrix
tablets because of its hydrophilic gel-forming property, non-
toxicity and cost effectiveness, insensitivity to the pH of the
biological medium and ease of production [7, 8]. Its good com-
pressibility also allows the preparation of hydrogel matrices by
direct compression [9]. Polyox consists of a family of high mo-
lecular weight polyethers with molecular weights ranging from
100,000 to 7,000,000. These materials have many uses in the
pharmaceutical industry, for instance, as dispersants, binders,
viscosifiers, mucoadhesives and hydrophilic matrix tablets [10,
11]. In many of these applications, the properties that polyox
imparts are dependent upon its molecular weight where both
swelling and dissolutions are faster in the case of the lower mo-
lecular weight forms, which results in higher release rates. On the
other hand, the extent of swelling is higher for higher molecular
weights, and this is the dominant factor in drug release [12].
Water diffusion into the matrix results in a destruction of the
polymer network. Once the macromolecules are disentangled,
the polymer chains diffuse through the unstirred layer surround-
ing the tablet, which is characterized by a distinct polymer con-
centration gradient.With increasingmolecular weight, the degree
of entanglement of the macromolecules increases and vice versa
[13]. When matrices containing PEO polymer come into contact
with water, forces of attraction chiefly hydrogen bonding, start
acting between polymer and water and the forces holding the
polymer segments together are therefore reduced, and the poly-
mer chains can swell consequently forming a gel layer at the
matrix surface. Water-soluble drugs are mainly released by dif-
fusion of dissolved drug molecules across the gel layer, while
poorly water-soluble drugs aremore likely to be released through
erosion of the gel [14]. The controlling mechanism of drug re-
lease from PEO tablets is dependent upon the drug solubility,
drug loading, the addition of water-soluble excipients and the
molecular weight of the PEOs [15].
As PEO’s can undergo chain cleavage via auto-oxidation
[16], the aim of this present study is to investigate the influence
of accelerated storage conditions (at 40 °C over 8 weeks) on
release rate of various drugs, with different solubilities, namely
propranolol HCl, theophylline and zonisamide from two differ-
ent molecular weight polyethylene oxides (750, and 303).
Materials and methods
Materials
PEO grades Sentry Polyox WSR 750 (ID166255),
MW = 3 × 105 and PEO 303 Sentry Polyox WSR 303
(ID166227) MW = 7 × 106 manufactured by Dow chemical
(Philadelphia, USA) and distributed by Colorcon (Kent, UK)
were used. Propranolol HCl, theophylline and zonisamide
were supplied by ELAN drug technologies (UK).
Magnesium Stearate (MgSt) (Fischer Scientific) was required
for its lubricating properties in preventing the produced tablet
from sticking to the die walls and punch faces. All solvents
used were of analytical grades and used as received.
Tablet preparation
Direct compression method was used to ensure less variability
in the final composition of the tablets. Tablet matrices were
made at ratio of 1:1 drug/polymer (w/w) and with the total
weight of 240 mg. To obtain a well-mixed composition, bina-
ry physical mixtures were blended in a TURBULA TF2
(Basel, Switzerland) machine for 10 min, prior to the direct
compression using Enerpac tableting machine procured from
Lobe Pharma with an 8-mm dye and punch at 1500 psi pres-
sure. The dye and the punch were lubricated with magnesium
stearate. Once prepared, all tablets were kept at room temper-
ature. For stability test purposes, three to four tablets were kept
at accelerated temperature 40 °C at time intervals of 2, 4 and
8 weeks in the oven in a closed glass container.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) was used to evaluate
thermal properties andmelting point of the polymer, drugs and
the formulations with a Mettler Toledo DSC1 tester. The
equipment was calibrated using indium and zinc at a scanning
rate of 10 °C/min in aluminium pans under nitrogen gas.
Approximately, 4–5 mg of sample was weighed and heated
at a range between 25 and 260 °C at a heating rate of 10 °C/
min. All samples were run in duplicates.
Determination of the tablet hardness
In order to measure the force needed to fracture the tablet, at
least three tablets were tested using tablet hardness tester 8 M
Dr. Schleuniger obtained from JB Pharmatron Ltd. The aver-
age values of the tablet hardness were also determined.
Dissolution parameters
Dissolution efficiency (DE720min) and mean dissolution rate
(MDR) were determined to represent the dissolution rate from
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various preparations. The dissolution efficiency (DE) of pharma-
ceutical dosage forms is defined as the area under the dissolution
curve up to a certain time, t, expressed as percentage of the area
of the rectangle described by 100% dissolution in the same time.
DE is described below by Eq. (1) [17]:
DE ¼
Zt
0
y dt
y100  t
 100% ð1Þ
where y is the percent drug release as the function of time, t, t
is the total time of drug release and y100 is 100% drug release.
An alternative parameter that describes the dissolution rate is
the mean dissolution time (MDT); the most likely time for a
molecule to be dissolved from a solid dosage form. Therefore,
MDT is the mean time for the drug to dissolve under in vitro
dissolution conditions. This is calculated using the following
Eq. (2) [17].
MDT ¼
Xn
j¼1
t jΔM j
Xn
j¼1
ΔM j
ð2Þ
where j is the sample number, tj is the midpoint of the jth time
period (easily calculated with [t + (t − 1)]/2 and ΔMj is the
additional amount of drug dissolved between tj and t–1.
Microsoft Excel was then used to calculate the cumulative
percentages of DE and MDT.
Dissolution test
Dissolution test was carried out in an ERWEKA DT 700 type
dissolution tester at 37 °C ± 0.1 °C. TheUSP paddlemethod [18]
was used to monitor the release profiles of the tablets. The dis-
solution medium was 900-ml deionised water and the paddles
rotated at 100 rpm. The samples were withdrawn and analysed at
every 15 min for up to 2 h, and thereafter, every 30 min up to
12 h. The concentration of the propranolol HCl, theophylline and
zonisamide was determined with a uv-vis spectrophotometer
(UV-1700 pharmaspec) provided by SHIMADZU at 290, 271
and 270 nm, respectively.
X-ray powder diffraction studies
The X-ray power diffraction (XRPD) patterns of PEO loaded
with various drugs at different storage time were determined
using a Siemens Diffractometer (Siemens, D5000, Germany)
with CuKa radiation (1.5405 Å). The instrument was calibrat-
ed using a silicon standard. The tube voltage and amperage
were set at 40 KV and 40 MA. The samples were analysed
between 2θ angles of 2 and 35° with a step size of 0.02° at 2
step/s.
Scanning electron microscope analysis
Electron micrographs of PEO matrices were obtained using a
scanning electronmicroscope (SEM) (Leica Cambridge S360,
UK) operating at 15 kV. The samples were mounted on a
metal stub with double-sided adhesive tape and coated under
vacuum with gold in an argon atmosphere prior to observa-
tion. Micrographs with different magnifications were recorded
to study the morphology of the solid dispersions.
Gel permission chromatography
Gel permeation chromatography (GPC) was used to study the
stability of the polymer by measuring its weight average mo-
lecular weight. A method similar to that described by Crowley
et al. [20] was used where all standards and samples were
prepared at 0.5% w/w concentrations in mobile phase under
gentle agitation for 10 h prior to injection. A PL-GPC 50
Model (Varian, UK) was used with a PL-aquagel-OH 8 μm
column (Agilent, UK). Samples were compared against stan-
dards (EasiVial®, Agilent, UK) to look at qualitative changes
in molecular weight. The mobile phase was double-distilled
HPLC water (Fisher UK) with 0.1 M sodium nitrate and was
pumped at a flow rate of 0.8 ml/min. The column was held at
an operating temperature of 35 °C during the analysis.
Viscosity study
Ground tablet samples were prepared at a 0.5% w/v concen-
tration in distilled water using gentle agitation on a radial
shaker for 12 h at 25 °C. They were tested using a
BrookfieldModel DV-II+ Pro viscometer (Harlow, UK) using
spindles 61 and 62 together with rotation speeds of 50 and
100 rpm as required; results presented are an average of three
runs.
Similarity factor (f2) measurement
In order to determine the similarity between the obtained drug
release profiles, the f2 was calculated according to Eq. (3)
below:
f 2 ¼ 50log 1þ 1
.
Rt–Ttð Þ2
h i−0:5
 100
 
ð3Þ
This being a mathematical treatment of the dissolution data
where n is the number of test points for the samples, wt is the
optional weight factor, Rt is the reference assay at time point t
and Tt is the test assay at time point t. An f2 value between 50
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and 100 suggests a similarity between the two release profiles
and the closer the value is to 100 the more similar or identical
the profiles are. Also, dissimalrity occurs with decreasing
values less than 50.
Results and discussion
The influence of storage conditions on true density
and tablet hardness
All formulations were relatively robust in terms of true densi-
ty. The results demonstrated that there was no significant dif-
ference (p > 0.05) between true density of PEO polymer for-
mulations before and after storage times even when stored for
8 weeks at accelerated temperature condition (40 °C). The
range of true density for fresh samples was between 1.22
and 1.25 g/cm3 and after 8 weeks, the true density was almost
the same (1.21–1.24 g/cm3) with just a very nominal change
of about 0.8–0.9%. In order to analyse the moisture content, a
Loss onDrying (LoD) test was performed to a constant weight
at temperature 10 °C below the melting point of PEO. LoD
analysis to elucidate the moisture content of the powder ob-
tained from the crashed tablets showed a very nominal change
in mass being about ∼1% w/w without any significant effect
on the tablets (e.g. density). It is apparent that PEO molecular
weight plays an influential role in determining the tablet hard-
ness. The effect of storage conditions on the tablet hardness of
various drugs with a ratio of drug/polymer (1:1) is shown in
Table 1. Looking at the hardness of different propranolol-
polyox (soluble drug) grades at time zero (fresh tablets), there
is a very modest increase of tablet hardness as polymer chain
length increased (Table 1). This could be due to a better
compactibility of PEO high molecular weight compared to
that of lower molecular weight (Table 1). The table also
showed that there was a decrease in the hardness of the tablets
when storage time progressed. In other words, generally, the
longer the storage time the lower the hardness. This might be
due to degradation, depolymerisation and crystallinity chang-
es of the aged PEO samples. Our results correlated with pre-
vious research carried out by Engineer et al. (2004), who in-
vestigated the effect of temperature on the hardness of
sustained-release diphenhydramine HCl tablets [19].
These results (Table 1) in addition shows the summary of
the hardness measured before and after storage times for the-
ophylline tablet matrices. It can be seen in Table 1 the mea-
sured values for batches containing PEO 750 were higher at
time 0 compared to aged tablets (2, 4 and 8 weeks). But all
tablets containing PEO 303-theophylline showed no signifi-
cant difference, as the hardness of the tablets were almost the
same before and after the storage (2, 4 and 8 weeks). For
example, tablet hardness of PEO 750 before and after storage
time was 95.5 and 86.1 N, respectively, while the range of
tablet hardness for PEO 303 was between 105 and 104 N.
Moreover, the results obtained for zonisamide tablet matri-
ces differed significantly compared to the polyox matrices
containing soluble and semi soluble drugs. It can be seen in
Table 1 that the average hardness of PEO 303 tablets stored for
0, 2, 4 and 8 weeks is 108, 114, 122 and 133 N, respectively,
whereas in the case of PEO 750, the hardness of the tablets
increased from 96 to 102 N when the storage time increased
from 0 to 8 weeks. It is apparent that PEO molecular weight
and solubility of zonisamide play an important role in the
tablet hardness, as a significant increase (ANOVA test
p < 0.05) in tablet hardness was observed for high molecular
weight PEO 303, while there was only a slight increase in the
hardness of tablets when lowmolecular weight PEO 750 poly-
mer was used.
The influence of storage condition and various molecular
weights of polyox on propranolol HCl release
In order to investigate the effects of storage conditions and
different molecular weight PEOs on drug release rate of pro-
pranolol HCl, dissolution test was conducted and the
Table 1 Effect of storage time on polyox tablet containing different
drugs hardness stored at 40 °C
PEO/drug Time (week) Hardness ratio 1:1
750/propranolol Fresh 93.1 ± 0.5
750 2 weeks 88.0 ± 0.5
750 4 weeks 84.0 ± 0.2
750 8 weeks 79.2 ± 0.1
303/propranolol Fresh 100.3 ± 0.1
303 2 weeks 94.5 ± 1.0
303 4 weeks 89.0 ± 0.5
303 8 weeks 84.1 ± 0.3
750/theophylline Fresh 95.5 ± 1.0
750 2 weeks 93.9 ± 0.5
750 4 weeks 91.5 ± 0.4
750 8 weeks 86.1 ± 0.1
303/theophylline Fresh 105.0 ± 0.5
303 2 weeks 104.5 ± 0.2
303 4 weeks 104.2 ± 0.4
303 8 weeks 104.0 ± 1.0
750/zonisamide Fresh 96.0 ± 0.5
750 2 weeks 98.1 ± 0.3
750 4 weeks 99.5 ± 0.3
750 8 weeks 102.0 ± 0.4
303/zonisamide Fresh 108.0 ± 1.0
303 2 weeks 114.0 ± 0.5
303 4 weeks 122.0 ± 2.0
303 8 weeks 133.0 ± 1.0
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dissolution profiles are shown in Fig. 1. Polymer molecular
weight is one of the primary parameters that dictate drug re-
lease rate and dissolution from solid dosage forms, and it
influences the in vivo bioavailability and therapeutic efficacy
[20]. Figure 1a summarizes the effect of molecular weight on
drug release, with low molecular weight PEO 750 achieving
faster drug release than high molecular weight PEO 303. Drug
release from high molecular weight PEO is principally
governed by the material swelling and diffusion rather than
by polymer erosion, and progressive decline of the drug’s
diffusive conductance in the growing swollen layer, making
the stronger gel layer less liable to erosion. Conversely, drug
release from low molecular weight PEO predominantly in-
volves swelling and erosion, in which the synchronization of
these may lead to release kinetics. The results also showed that
lower molecular weight PEO 750 exhibited about 50% of drug
release in less than 2 h, while in case of PEO 303 almost 60%
of drug release occurred within 6 h. It is well known, for a
water-soluble polymer, the higher the molecular weight the
higher the viscosity of the polymer solution and the slower
the swelling and dissolution rate [21]. The results showed that
there was a gradual release, followed by a progressive increase
in drug release with the higher molecular weight polyox. For
soluble drugs like propranolol (solubility of propranolol HCl
is 50.0 mg/ml in water), the swelling of the polymer is due to
the penetration of the medium into the matrix system that
elicits a displacement of the solid particles of the drug in the
gel layer [22, 23]. In general, the solubility of the drug may
govern the type of the polymer to be used, and the need to
formulate with polymer mixtures, and the incorporation of co-
excipients [23]. Figure 1b, c shows that the storage time also
had an impact on propranolol HCl release from polyox 750 or
303. The drug release was faster at longer storage times and it
can be ranked as 8 weeks >4 weeks >2 weeks >0 week. Upon
accelerated storage conditions, it is apparent that there is a
shortening in polymer chain length, suggesting the occurrence
of PEO oxidation, thus instability causing faster drug release
with time [24]. On the basis of the above information, some of
the features in the dissolution rate of PEO can be confirmed
particularly by similarity factor (f2) values. All f2 values for
PEO 750 and 303 (lower and higher molecular weights) are
reported to be less than 50 when the fresh tablets were com-
pared with the aged polyox tablets containing propranolol
which is an indication of no similarity between their release
profiles (Table 2). The effect of humidity condition during the
storage did not have significant impact on the release profiles
of propranolol HCl from the PEO matrices. As can be seen in
Fig. 2 that while changing the relative humidity during the
storage of the samples from 16% to very high 75%RH values,
the release profiles for both grades remained almost the same.
However, a slight increase in the release profile of aged PEO
303 samples (4 and 8 weeks) was observed when the humidity
was increased from 16% to higher values. This could possibly
be attributed to the fast material swelling and diffusion on high
relative humidity condition and hence the faster release of
water-soluble propranolol.
Dissolution efficiency (DE) and mean dissolution time
(MDT) were used to compare the dissolution data as described
by Khan (1975) [17]. The results of fitting the dissolution data
with the dissolution criteria are shown in Table 3. Dissolution
efficiency values are consistent with dissolution profiles and
these data confirmed that the drug release rate from PEO 750
Fig. 1 The effect of storage time and various molecular weights on drug
release of propranolol at (1:1) drug/polymer ratio and stored at 40 °C. a
PEO 750/303 effect of MV. b PEO 750. c PEO 303
Table 2 Similarity values f2 for propranolol, theophylline and
zonisamide PEO tablet release profiles at different storage times
compared to controls at time zero for (1:1) ratio
Polyox/drugs 2 weeks 4 weeks 8 weeks
750 (propranolol) 45.5 21.3 20.6
303 23.7 27.4 12.4
750 (theophylline) 50.5 42.2 32.1
303 76.3 63.5 70.2
750 (zonisamide) 64.3 59.6 55.1
303 65.1 73.6 56.6
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as lower molecular weight is faster when they are stored at
40 °C for different times compared to the fresh tablets. For
instance, the dissolution efficiency value of PEO 750 at time 0
was 62% whereas this value increased to 92% for tablet ma-
trices stored for 8 weeks at 40 °C. A similar pattern was ob-
tained for the higher molecular weight PEO 303 (Table 3). The
results obtained for MDTconfirmed the same trend (with DE)
for both low and high molecular weight PEO. For instance,
MDT for fresh PEO 750 tablets was 2.59 h while this value
decreased to 0.96 h at 8-week storage time which is an indi-
cation of very fast drug release for the tablets stored at 40 °C
(Table 3).
The changing in molecular weight usually measure by
GPC. Figure 3 shows GPC profile for lower molecular weight
PEO 750. As can be seen from Fig. 3 that the sample stored at
elevated temperature (40 °C) over 8 weeks indicated a signif-
icant shift to longer retention times as results of ageing show-
ing a noteworthy decline in the molecular weight of the aged
sample. During storage, PEO can degrade to lower molecular
weight with shorter chain length and lower solution viscosity.
Its physical appearance becomes soft, waxy with a distinctive
Table 3 Effect of storage time on dissolution parameters of propranolol
PEO tablet matrices
PEO Time (weeks) DE (%) MDT(h)
750 0 75.0 ± 2.81 2.59 ± 1.24
750 2 84.0 ± 4.0 1.81 ± 0.26
750 4 88.0 ± 0.83 1.48 ± 0.04
750 8 92.0 ± 0.26 0.96 ± 0.03
303 0 60.0 ± 4.06 3.93 ± 0.07
303 2 68.0 ± 1.68 3.72 ± 0.03
303 4 85.0 ± 1.15 1.93 ± 0.02
303 8 91.0 ± 0.93 1.16 ± 0.01
DE dissolution efficiency, MDT mean dissolution time
Fig. 2 The effect of different
relative humidity on the drug
release of propranolol at 16–75%
RH on storage
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smell [20]. Our results correlated with previous research in-
vestigating the effect of storage time on the molecular weight
of sustained-release tablets [20, 25].
Another approach to confirm the effect of storage time on
PEO samples is viscosity testing which is done by previous
researcher to revise the poverty and degradation of Polyox®
[26, 27]. Our data are in good correlation with the previous
researchers who stated that a significant decreasing in molec-
ular weight of PEO was occurred when the PEO samples
stored at elevated temperature. Viscosity data (Table 4) clearly
shows that there is major reduction in viscosity of fresh sam-
ples when they were stored at elevated temperature at 40 °C
for 8 weeks. For instance, fresh PEO 750 showed a viscosity
of 60 (cp), while it reduced to 52 (cp) at 8-week storage.
Similar pattern was obtained for higher molecular weight
PEO 303 (Table 4).
The influence of storage time and various molecular
weights of PEOs on theophylline release
Theophylline with less solubility (8 mg/ml) compared to pro-
pranolol HCl was selected as another model drug with mod-
erate solubility to investigate the effect of ageing on the drug
release from polyox 750 and 303 matrices. The release pro-
files of theophylline from fresh polyox samples are presented
in Fig. 4a. The results showed that, once again, the drug re-
lease was faster from low molecular weight PEO 750 and
slower from high molecular weight PEO 303. This suggests
that the higher molecular weight of aged PEO matrices have
the ability to swell and form stronger gel upon hydration
which is less likely to erode. These findings are in good agree-
ment with the results obtained in various studies [26–28]. The
same conclusion was previously drawn for highly water-
soluble drug. The reason for this pattern has been presented
earlier in the case of propranolol HCl matrices [26–28].
As expected, comparison of the dissolution profiles of fresh
matrices containing two different drugs so far showed that the
drug release is slower from the matrices containing
theophylline (Fig. 4a) compared to polyox matrices contain-
ing propranolol HCl (Fig. 4a). This could be attributed to the
less solubility of theophylline in the dissolution medium com-
pared to propranolol HCl compared to the release profiles of
aged polyox samples containing highly water-soluble drugs
particularly in case of polyox 303.
It is interesting to note that the effect of storage time on
theophylline release was different compared to the release
profiles of aged polyox samples containing highly water-
soluble drugs particularly in case of polyox 303. In the case
of polyox 750, the drug release became faster at longer storage
times (8 > 4 > 2 > 0 weeks (Fig. 4b). In contrast, Fig. 4c shows
no significant differences between the fresh and the aged tab-
lets (8 weeks) when polyox 303 was used. It is apparent from
the figure that all release profiles were super imposable with
no significant changes in the drug release. This is supported by
Bigger et al. (1991), who investigated the effects of molecular
weight and thermal oxidation on the dynamic mechanical re-
sponse of polyethylene oxide [28]. Comparing the release
profiles of water-soluble drug diltiazem with theophylline
from polyox 750 showed that the gap between the release
profiles of fresh samples and aged samples is much smaller
for theophylline (Fig. 4b) compared to matrices containing
highly water-soluble drugs (Fig. 1b).
This further investigated in separate studies that correlate
our data with respect to PEO stability. The increase in drug
release rate observed varies with molecular weight [29, 30].
They observed that the partly soluble drug theophylline tend
to follow diffusion/erosion release mechanism depending on
the grades of polymer used. From their data, the mechanism of
Fig. 3 GPC profiles for PEO 750
fresh compared to 8-week
samples stored at 40 °C
Table 4 Viscosity data for ground tablet samples containing PEO 750
and 303 at time zero and 8 weeks storage at 40 °C
PEO PEO 750/viscosity (cp) PEO 303/viscosity (cp)
Fresh 60 736
8 weeks 52 109
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theophylline release from the higher molecular weight matri-
ces was by diffusion and from the lower molecular weight by
erosion.
To confirm the above findings, the similarity factor (f2) was
calculated and data are presented in Table 2. This table shows
that all f2 values for polyox 750 are less than 50 except tablets
stored for 2 weeks which is an indication of no similarity
between fresh sample and aged polyox formulations (4 and
8 weeks). In the case of polyox 303, all f2 values were greater
than 50 indicating similarity between fresh and aged formula-
tions. All these f2 values supported the conclusion drawn for
release profiles of fresh and aged polyox matrices containing
theophylline. Dissolution efficiency (DE) and mean dissolu-
tion time (MDT) were also used to compare the dissolution
data as described by Khan (1975). The results of fitting the
dissolution data with the dissolution criteria are shown in
Supp. Table 1. Dissolution efficiency values are consistent
with dissolution profiles and these data confirmed that the
drug release rate from PEO 750 is faster when they are stored
at 40 °C for different times. For instance, the dissolution effi-
ciency value of PEO 750 at time 0 was 80.0% whereas this
value increased to 90.0% for aged matrices stored for 8 weeks
at 40 °C.
As can be seen from Supp. Table 1, almost similar DE
values were obtained for fresh polyox 303 matrices (34.0%)
and aged matrices for 8 weeks (33.0%). The results obtained
for MDT confirmed the same conclusion mentioned above as
MDT for fresh PEO 750 tablets was 2.35 h while this value
decreased to 1.36 h at 8 weeks storage time which is an indi-
cation of faster drug release for the tablets stored at 40 °C for
8 weeks. No significant changes (p > 0.05) were observed for
MDT in the case of fresh and aged polyox 303 matrices.
Effect of storage time and molecular weight of PEOs
on zonisamide release
Zonisamide was selected as a very poorly water-soluble drug
(0.8 mg/ml) in the present study to cover the full range of
solubility. In order to investigate the effects of storage condi-
tions and different molecular weight PEOs on release rate of
zonisamide, various PEO molecular weights (750 and 303)
were chosen as the inert matrix and dissolution profiles are
shown in Fig. 5. As expected again, the drug release was faster
from low molecular weight of polyox compared to high
Fig. 4 The effect of storage time and various molecular weights on drug
release of theophylline at (1:1) drug/polymer ratio and stored at 40 °C. a
PEO 750/303 effect of molecular weight. b PEO 750. c PEO 303
Fig. 5 The effect of storage time and various molecular weights on drug
release of zonisamide at (1:1) drug/polymer ratio and stored at 40 °C. a
PEO 750/303 effect of molecular weight. b PEO 750. c PEO 303
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molecular weights Fig. 5a. Thus, concluding that molecular
weight has immense bearing upon the amount of drug released
from tablets and the thermal oxidation of PEO being highly
dependent upon this [20]. The reason for this release trend was
discussed in detail earlier in this study. Figure 5b, c shows the
drug release profiles of the two different molecular weight
(303 and 750) PEO matrices containing zonisamide at differ-
ent storage times of 0, 2, 4 and 8 weeks. As it can be seen from
the graphs that in the 12-h dissolution run, the amount of drug
released increases in both PEO 303 and 750; however, as
expected, drug release from PEO 750 is faster compared to
PEO 303. The dissolution test for PEO 750 showed almost
100% drug release within 5 h of the dissolution test for all
storage times, whereas for PEO 303 even after 12 h of disso-
lution test, 100% drug release is not obtained and the graph
continues to increase. This further confirmed that high molec-
ular weight PEO has the potential to be used as the novel
sustained-release carrier for the oral delivery of zonisamide.
However, in order to achieve the therapeutic level of
zonisamide, a lower molecular weight grade of PEO may be
more suitable other than PEO 303 and/or longer period disso-
lution time, due to slower drug release over 12-h period of
time as seen in this experiment. This is due to poor solubility
of zonisamide in the dissolution medium. In terms of stability,
for PEO 750, a slight difference in drug release could be ob-
served after storing the samples under stress conditions. On
the other hand, drug release from PEO 303 stored for the first
4 weeks is similar; however, it decreases significantly after
8 weeks. As no other excipients were added in these formula-
tions, the only factor that could possibly affect the dissolution
is the drug molecule itself. This suggests that not only the
physical property of the polymer determines the release
changes from the dosage form in the course of storage but
also the properties of the drug molecules such as solubility
may affect the release kinetics of PEO 303 matrices.
On the basis of above information, some of the features in
the dissolution rate of PEO can be elaborated particularly by
similarity factor (f2) values (Table 2). It is evident from
Table 2 as all f2 values for zonisamide with both PEO 750
and 303 are reported to be greater than 50 when the fresh
tablets were compared to aged polymer formulation which is
an indication of similarity between their release profiles. This
suggests the changes in the drug release with storage time
were not significant.
Dissolution efficiency (DE) and mean dissolution time
(MDT) were used to compare the dissolution data and they
are shown in Supp. Table 2. Dissolution efficiency values are
consistent with dissolution profiles and these data confirmed
that the drug release rate from PEO 750 is slightly faster when
they are stored at 40 °C for different times although, it was not
significant. For instance, the dissolution efficiency value of
PEO 750 at time 0 was 84.0% whereas this value only in-
creased to 87.0% for aged matrices stored for 8 weeks at
40 °C which is an indication of no significant changes in aged
polyox samples over 8-week storage time.
In contrast, as it can be seen from Supp. Table 2 for higher
molecular weight PEO 303, there was slight decreasing in DE
values during storage time which is indicated possibly no
significant degradation was happened over 8-week storage
time. For example, DE values for fresh and 8-week samples
were 35.0 and 28.0%, respectively. The results obtained for
MDT confirmed the same conclusion, as MDT for fresh PEO
303 tablets was 4.11 hwhile this value increased to 4.16 h at 8-
week storage time which is an indication of a slight decrease
in the dissolution rate as the time progressed.
All these results indicated that the drug release from
aged polyox samples containing poorly water-soluble
drugs are more stable than the aged polyox matrices con-
taining highly water-soluble drug (propranolol HCl). This
shows that when various drugs are formulated as
controlled-release matrices using polyox powders, the sol-
ubility of drug and molecular weight of polyox should be
taken into consideration to achieve a suitable approach
should be adopted to a stable release profile for drugs
with different solubility. Since zonisamide is a very poor-
ly soluble drug and the ratio of polymer to drug used in
the formulation is 1:1, it can be assumed that the hydra-
tion and swelling of the polymer are also affected by the
drug molecule for which the result obtained is as expect-
ed. The effects of drug molecular interaction with various
polymers were studied and can be found in literature but
not for PEO. As PEO are a non-ionic material, interaction
between drug and polymers is less likely to take place
other than hydrogen bonding (H bond). Study by
Sarisuta et al. (1999) revealed that erythromycin molecule
and non-ionic HPMC polymer chain would probably in-
teract through hydrogen bonding [31]. Moreover, comput-
er simulation by Kiss et al. (2008) showed that the inter-
action between theophylline and poly (ethylene oxide) is
stronger and the energy gain of the H bond between these
two molecules is greater than in the case of metronida-
zole. Thus, by using this phenomenon, it can be said that
a possible interaction between the polymer and the drug
molecule may have taken place and the new bond struc-
ture between them may perhaps prevent oxidation and
have altered the dissolution. Additionally, the –OH end
groups in PEO are capable of H-bond formation with wa-
ter molecules [20]. Thus, the lower molecular weight PEO
750 hydrates faster which facilitates the penetration of the
water molecule into the matrix due to the presence of
more –OH groups. On the other hand, PEO 303 forms a
much thicker gel, leaving less opportunity for water mol-
ecules to get imbibed and interact with drug molecules
likewise because of this the drug release from PEO 303
is slower [32, 33]. Moreover, as explained earlier with
time formulations containing PEO 303 required more
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strength to break the tablets (See Table 1). Thus, combin-
ing both the hardness and dissolution data, it can be pre-
dicted that the interaction between the polymer and the
drug may have increased with storage time which lead
to stronger gel formation and therefore significantly de-
creased drug release from PEO 303.
In other words, although the samples containing proprano-
lol HCl showed a significant (p < 0.05) reduction in the en-
thalpies after 8 weeks compared to the fresh samples, the
reduction in the enthalpies of fresh samples including poorly
soluble drug such zonisamide is not as significant as aged
samples. This indicates that special care must be taken when
formulating controlled-release matrices containing highly
water-soluble drugs such as propranolol with polyox
polymers.
SEM and XRPD study
SEM was used to find any changes in particle shape and mor-
phology of PEO matrices before and after storage conditions
when they were stored at elevated temperature at 40 °C for
8 weeks. The results of SEM for various molecular weights
PEO are shown in Fig. 6. The figure shows there was no
significant change in morphology of PEO matrices before
and after the storage. This means that there was no significant
evidence detected by SEM that could correlate the changes in
the dug release with storage time.
XRDwas also used to see if any changes in the crystallinity
of the samples could be found after storing them for 8 weeks at
40 °C. Figure 7 shows the XRD patterns of the different for-
mulations with molecular weight PEO (750 and 303) before
Fig. 6 SEM of various molecular
weight PEOs at zero and week 8
storage times that were obtained
at 25 °C
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and after storage at 40 °C. XRPD results demonstrated that the
solid state of PEO before and after storage time was similar.
The only detectable difference between the fresh and aged
polyox samples is the intensity of the peaks. The aged samples
showed slightly smaller intensity compared to the fresh sam-
ples. This may be an indication of less crystallinity for the
aged samples which might be responsible for faster drug re-
lease from aged polyox samples. This was also confirmed by
DSC data in which aged samples showed lower enthalpies
compared to the fresh samples.
DSC analysis
The thermal behaviour of the fresh and aged ground tablet
matrices was studied by DSC and the results are presented
in Fig. 8 (Table 5 and Supp. Tables 3 and 4). As can be seen
from Fig. 8, there was a shift in melting points of polyox
towards the lower temperatures compared to the fresh samples
when propranolol was used as a model drug. DSC traces were
further analysed in terms of their enthalpies and the results are
shown in Table 5. DSC traces clearly showed a major change
in thermal transitions following the storage of the matrix tab-
lets at 40 °C where the enthalpy values decreased as the stor-
age time increased. This indicates that there is some sort of
plasticisation effect on the aged sample compared to the fresh
samples. The reduction in the enthalpy could be due to a
reduction in viscosity (see Table 4) and a decrease in
molecular weight. The GPC techniques have already demon-
strated that the aged samples may have changed to a lower
molecular weight polyox upon storage (see Fig. 2). The data in
Table 5 also indicated that there were major reductions in the
temperature of the onset and peak of the melting endothermic
for PEO grades investigated. The reduction in temperature or
enthalpy became more pronounced as storage time was in-
creased from 2 to 8 weeks.
For theophylline, it is interesting to note that in the case of
aged polyox 303 no changes in the melting points of aged
samples were observed compared to the fresh samples
(Fig. 8 and Supp. Table 3). This could be the reason for similar
dissolution profiles for fresh and aged polyox 303 matrices.
This indicates that degradation did not occur for aged polyox
303 samples due to the presence of the less water-soluble
drug, theophylline. The above finding was also confirmed
by the enthalpy data reported in Supp. Table 3. It is clear from
the table that in the case of polyox 750, the enthalpy values
decreased as the storage time progressed but this was not the
case for polyox 303 samples as similar enthalpies were obtain-
ed. This indicates that aged polyox 303 samples may retain
their molecular weight in the presence of theophylline.
In contrast, zonisamide showed a different thermal event
compared to that of other two model drugs. The results ob-
tained from the DSC traces showed that there was no signif-
icant reduction in peak melting temperatures upon storage for
both polyox 750 and 303. This suggests that there was no
Fig. 7 X-ray diffraction (XRD)
patterns of various molecular
weights PEO750 and 303 at zero
and week 8 storage times
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noteworthy shortening in polymer chain length through aero-
bic auto-oxidation [34]. DSC traces also clearly demonstrated
that the extensive changes were not visible in any of the
polyox grades used (Fig. 8). These results are confirmed by
the DSC data in Supp. Table 4 which includes the enthalpy,
onset and melting peak data of all zonisamide based samples.
It is evident from the Supp. Table 4 that the solubility of
zonisamide in the samples prevented the big reduction in the
enthalpies of the polyox as it occurred for the samples con-
taining highly soluble drug propranolol HCl.
Conclusions
Various studies relating directly to the investigation of PEOs
have suggested that a particular advantage of these polymers
Fig. 8 DSC thermograms for ground propranolol, theophylline and zonisamide matrix tablets: PEO 750 and 303 before and after storage times of 0, 2, 4
and 8 weeks
Table 5 DSC parameters of various PEO ground propranolol matrix tablets at different storage times (0, 2, 4 and 8 weeks)
PEO grade Time (week) Enthalpy (J/g) Onset (°C) Peak (°C)
303 Fresh
2 weeks
4 weeks
8 weeks
−167.0 1:0 65.00:5 71.01.0
−155.00:1 63.01:0 69.51.0
−142.01.0 62.90:6 69.00:5
−135.01.0 61.50:4 68.10:3
750 Fresh −133.00:1 64.10:1 70.00:2
2 weeks −126.00:2 63.51.0 69.30:4
4 weeks −119.00:3 62.00:3 69.01.0
8 weeks −114.50:5 60.00:7 67.70:3
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may be the rapid gelling of the polymer upon hydration
followed by a significant swelling of the tablet system.
However, when matrices made from fresh PEO are stored at
elevated temperature, a significant degradation and
depolymerisation as a result of storage time may occurred on
polymer structure which was evident by dissolution profiles,
GPC, viscosity data and DSC traces in the present study. The
reduction in molecular weight progressed with time through-
out the study and could be clearly observed using GPC and
DSC analyses. Generally, the changes in molecular weight led
to dramatic increases in the release rate of the water-soluble
drug (propranolol HCl). After 8 weeks of storage, all the re-
lease profiles including those for the higher molecular weight
grade PEO 303 clearly exhibited an increased release profile.
Whereas these changes in the drug release were only observed
in the case of polyox 750 when medium water-soluble drug
(theophylline) was used. On the other hand, polymer formu-
lations including semi soluble drug theophylline with PEO
303 and zonisamide as a poorly soluble drug containing either
polyox 750 or 303 showed a stable drug release for 8 weeks. It
can be concluded that the molecular weight and the solubility
of drugs played major role in controlling the drug release from
both the fresh and aged polyox matrices. As a futuristic ap-
proach, it will be worth examining the effect of a range of
controlled relative humidity while the samples are stored at
accelerated temperature over a prolonged period of time.
Therefore, the explorative study will provide a detailed exper-
imental gateway of the effect of temperature, storage time and
humidity on the stability of PEO matrix tablets.
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